Silexion Therapeutics Corp — Form 8-K
Filed September 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Silexion dosed the first patient in its global Phase 2/3 clinical trial of SIL204 on September 30, 2026, at Tel Aviv Sourasky Medical Center in Israel. The trial is a randomized, controlled study enrolling approximately 18 patients in a safety run-in cohort followed by ~166 patients in a randomized expansion cohort, evaluating SIL204 combined with standard chemotherapy versus chemotherapy alone in locally advanced pancreatic cancer patients with KRAS mutations. SIL204 uses a novel dual-route delivery combining EUS-guided intratumoral injection and subcutaneous dosing.
Why this rating
Major clinical milestone for $4.2M-asset company—first Phase 2/3 patient dosing is defining transition to active execution. For a clinical-stage biotech, advancement of lead program is material but not guarantee of success; trial enrollment and efficacy unknown.
Tradability signal
NO TRADE
No trade: price $0.01 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $0.01 | +10 min · unknown $0.01 ▲ 0.00% | +30 min · unknown $0.01 ▲ 0.00% | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.